CONMED Competitors

Abbott Laboratories (NYSE:ABT) and CONMED (NASDAQ:CNMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Abbott Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, CONMED has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Institutional & Insider Ownership

73.1% of Abbott Laboratories shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 4.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dividends

Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. CONMED pays out 30.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Abbott Laboratories and CONMED's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Abbott Laboratories and CONMED, as provided by MarketBeat.

Abbott Laboratories currently has a consensus price target of $115.1250, suggesting a potential upside of 5.62%. CONMED has a consensus price target of $98.00, suggesting a potential upside of 18.23%. Given CONMED's higher possible upside, analysts plainly believe CONMED is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Abbott Laboratories and CONMED's top-line revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Abbott Laboratories beats CONMED on 11 of the 15 factors compared between the two stocks.

Medtronic (NYSE:MDT) and CONMED (NASDAQ:CNMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Medtronic has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, CONMED has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Medtronic and CONMED's net margins, return on equity and return on assets.

Institutional & Insider Ownership

79.9% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 4.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Medtronic and CONMED's top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than CONMED. Medtronic is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Medtronic and CONMED, as provided by MarketBeat.

Medtronic currently has a consensus price target of $117.8571, suggesting a potential upside of 9.20%. CONMED has a consensus price target of $98.00, suggesting a potential upside of 18.23%. Given CONMED's higher possible upside, analysts plainly believe CONMED is more favorable than Medtronic.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Medtronic pays out 50.5% of its earnings in the form of a dividend. CONMED pays out 30.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Medtronic beats CONMED on 12 of the 17 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

CONMED has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Profitability

This table compares CONMED and Intuitive Surgical's net margins, return on equity and return on assets.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. 4.4% of CONMED shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CONMED and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Intuitive Surgical, as provided by MarketBeat.com.

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Intuitive Surgical has a consensus target price of $720.4737, suggesting a potential upside of 1.22%. Given CONMED's stronger consensus rating and higher possible upside, research analysts clearly believe CONMED is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats CONMED on 10 of the 14 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Stryker (NYSE:SYK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility and Risk

CONMED has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares CONMED and Stryker's net margins, return on equity and return on assets.

Institutional & Insider Ownership

71.0% of Stryker shares are held by institutional investors. 4.4% of CONMED shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CONMED and Stryker's gross revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than CONMED. Stryker is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Stryker, as provided by MarketBeat.com.

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Stryker has a consensus target price of $220.68, suggesting a potential upside of 2.77%. Given CONMED's stronger consensus rating and higher possible upside, research analysts clearly believe CONMED is more favorable than Stryker.

Dividends

CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.1%. CONMED pays out 30.3% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Stryker beats CONMED on 15 of the 18 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility and Risk

CONMED has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Profitability

This table compares CONMED and Becton, Dickinson and's net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.2% of Becton, Dickinson and shares are held by institutional investors. 4.4% of CONMED shares are held by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CONMED and Becton, Dickinson and's gross revenue, earnings per share and valuation.

Becton, Dickinson and has higher revenue and earnings than CONMED. Becton, Dickinson and is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Becton, Dickinson and, as provided by MarketBeat.com.

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Becton, Dickinson and has a consensus target price of $280.8571, suggesting a potential upside of 16.06%. Given CONMED's stronger consensus rating and higher possible upside, research analysts clearly believe CONMED is more favorable than Becton, Dickinson and.

Dividends

CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.3%. CONMED pays out 30.3% of its earnings in the form of a dividend. Becton, Dickinson and pays out 27.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Becton, Dickinson and beats CONMED on 13 of the 17 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

CONMED has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares CONMED and Boston Scientific's net margins, return on equity and return on assets.

Insider & Institutional Ownership

90.2% of Boston Scientific shares are owned by institutional investors. 4.4% of CONMED shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CONMED and Boston Scientific's top-line revenue, earnings per share (EPS) and valuation.

Boston Scientific has higher revenue and earnings than CONMED. Boston Scientific is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Boston Scientific, as provided by MarketBeat.com.

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Boston Scientific has a consensus target price of $44.6522, suggesting a potential upside of 21.14%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than CONMED.

Summary

Boston Scientific beats CONMED on 12 of the 15 factors compared between the two stocks.